EA201791058A1 - Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) - Google Patents
Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)Info
- Publication number
- EA201791058A1 EA201791058A1 EA201791058A EA201791058A EA201791058A1 EA 201791058 A1 EA201791058 A1 EA 201791058A1 EA 201791058 A EA201791058 A EA 201791058A EA 201791058 A EA201791058 A EA 201791058A EA 201791058 A1 EA201791058 A1 EA 201791058A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sstr4
- agonists
- receptor subtype
- somatostatin receptor
- oxazazepan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Изобретение относится к производным морфолин- и 1,4-оксазепан-амида общей формулы (I), которые являются агонистами соматостатинового рецептора подтипа 4 (SSTR4), пригодным для предупреждения или лечения заболеваний, связанных с SSTR4. Кроме того, изобретение относится к способам получения фармацевтических композиций, а также к способам получения соединений в соответствии с изобретением.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14193185 | 2014-11-14 | ||
PCT/EP2015/076440 WO2016075240A1 (en) | 2014-11-14 | 2015-11-12 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201791058A1 true EA201791058A1 (ru) | 2017-11-30 |
EA032104B1 EA032104B1 (ru) | 2019-04-30 |
Family
ID=51904765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791058A EA032104B1 (ru) | 2014-11-14 | 2015-11-12 | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) |
Country Status (14)
Country | Link |
---|---|
US (2) | US10071974B2 (ru) |
EP (1) | EP3218372B1 (ru) |
JP (1) | JP6641367B2 (ru) |
KR (1) | KR20170082632A (ru) |
CN (1) | CN107108592B (ru) |
AU (1) | AU2015345070A1 (ru) |
BR (1) | BR112017009595A2 (ru) |
CA (1) | CA2965566A1 (ru) |
CL (1) | CL2017001181A1 (ru) |
EA (1) | EA032104B1 (ru) |
IL (1) | IL251465A0 (ru) |
MX (1) | MX370366B (ru) |
PH (1) | PH12017500821A1 (ru) |
WO (1) | WO2016075240A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2699580T3 (ru) | 2014-01-24 | 2018-02-24 | ||
EP3053452A1 (en) * | 2015-01-16 | 2016-08-10 | Interquim, S.A. | Naturally derived colour stabilizer |
EP3490566A4 (en) * | 2016-07-29 | 2020-03-11 | Insmed Incorporated | DETERMINED (2S) -N - [(1S)] - 1-CYANO-2-PHENYLETHYL-1,4-OXAZEPAN-2-CARBOXAMIDES FOR TREATING BRONCHIEKTASIS |
JP7343170B2 (ja) | 2017-05-12 | 2023-09-12 | ボード オブ トラスティーズ オブ ザ サザン イリノイ ユニバーシティ オン ビハーフ オブ サザン イリノイ ユニバーシティ エドワーズビル | 3,4,5-三置換-1,2,4-トリアゾールおよび3,4,5-三置換-3-チオ-1,2,4-トリアゾール、ならびにそれらの使用 |
US11912687B2 (en) | 2017-05-12 | 2024-02-27 | Board of Trustees of the Southern Illinois University | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof |
SG11202008398XA (en) * | 2018-03-01 | 2020-09-29 | Takeda Pharmaceuticals Co | Piperidinyl-3-(aryloxy)propanamides and propanoates |
TW202146403A (zh) * | 2020-05-21 | 2021-12-16 | 大陸商廣州費米子科技有限責任公司 | 含氮飽和雜環化合物及其製備方法、藥物組合物和應用 |
CN113929693B (zh) * | 2020-07-13 | 2023-05-09 | 广州费米子科技有限责任公司 | 含氮杂环化合物、药物组合物和应用 |
TW202400577A (zh) | 2021-09-14 | 2024-01-01 | 美商美國禮來大藥廠 | Sstr4促效劑鹽 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1833836B1 (en) | 2004-11-12 | 2011-12-21 | Bristol-Myers Squibb Company | Imidazo-fused thiazolo [4,5-b] pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
WO2010059922A1 (en) | 2008-11-21 | 2010-05-27 | Ligand Pharmaceuticals Incorporated | Pyrrolidine carboxamide compounds |
EP2683697B1 (en) | 2011-03-10 | 2017-09-06 | Lupin Atlantis Holdings SA | Substituted morpholines as modulators for the calcium sensing receptor |
-
2015
- 2015-11-12 EA EA201791058A patent/EA032104B1/ru not_active IP Right Cessation
- 2015-11-12 EP EP15793840.8A patent/EP3218372B1/en active Active
- 2015-11-12 WO PCT/EP2015/076440 patent/WO2016075240A1/en active Application Filing
- 2015-11-12 US US15/526,361 patent/US10071974B2/en active Active
- 2015-11-12 KR KR1020177016161A patent/KR20170082632A/ko unknown
- 2015-11-12 BR BR112017009595A patent/BR112017009595A2/pt not_active Application Discontinuation
- 2015-11-12 AU AU2015345070A patent/AU2015345070A1/en not_active Abandoned
- 2015-11-12 CA CA2965566A patent/CA2965566A1/en not_active Abandoned
- 2015-11-12 CN CN201580062239.4A patent/CN107108592B/zh active Active
- 2015-11-12 JP JP2017525799A patent/JP6641367B2/ja active Active
- 2015-11-12 MX MX2017006231A patent/MX370366B/es active IP Right Grant
-
2017
- 2017-03-30 IL IL251465A patent/IL251465A0/en unknown
- 2017-05-04 PH PH12017500821A patent/PH12017500821A1/en unknown
- 2017-05-10 CL CL2017001181A patent/CL2017001181A1/es unknown
-
2018
- 2018-07-30 US US16/048,665 patent/US10577336B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017533930A (ja) | 2017-11-16 |
EP3218372B1 (en) | 2020-05-20 |
CN107108592A (zh) | 2017-08-29 |
US20170320838A1 (en) | 2017-11-09 |
JP6641367B2 (ja) | 2020-02-05 |
MX2017006231A (es) | 2017-07-31 |
EP3218372A1 (en) | 2017-09-20 |
EA032104B1 (ru) | 2019-04-30 |
IL251465A0 (en) | 2017-05-29 |
CL2017001181A1 (es) | 2018-02-02 |
US10577336B2 (en) | 2020-03-03 |
CA2965566A1 (en) | 2016-05-19 |
US10071974B2 (en) | 2018-09-11 |
WO2016075240A1 (en) | 2016-05-19 |
BR112017009595A2 (pt) | 2017-12-19 |
US20180339971A1 (en) | 2018-11-29 |
MX370366B (es) | 2019-12-11 |
KR20170082632A (ko) | 2017-07-14 |
PH12017500821A1 (en) | 2017-10-02 |
AU2015345070A1 (en) | 2017-04-20 |
CN107108592B (zh) | 2021-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
PH12017500941A1 (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
EA201501122A1 (ru) | Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4) | |
MY194262A (en) | Inhibitors of ret | |
EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
MY192717A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
EA201891336A1 (ru) | Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj | |
EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
EA201591889A1 (ru) | 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
EA201791096A1 (ru) | 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139 | |
MX2018012085A (es) | Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119. | |
EA201691141A1 (ru) | Соединения против ccr6 | |
EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
MY176521A (en) | Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof | |
EA201691632A1 (ru) | Пиразины в качестве модуляторов gpr6 | |
EA201691413A1 (ru) | Селективные антагонисты nr2b | |
IN2014CH00304A (ru) | ||
EA201692246A1 (ru) | Способ получения 2,6-диметилбензохинона |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |